Two Weeks, One Pill? China’s Ultra-Long-Acting Oral Diabetes Drug Enters the Long-Acting Era

In recent years, as the global number of people living with diabetes continues to rise, diabetes treatment has gradually shifted from simple glucose lowering toward a new era of long-term chronic disease management. For many patients, blood sugar control is no longer the only concern. Increasingly, patients also care about treatment convenience, low hypoglycemia risk, and long-term protection for vital organs such as the heart and kidneys.

Against this backdrop, China’s independently developed ultra-long-acting oral diabetes drug, Cofrogliptin, has attracted growing attention. Dengyue has observed that, as an original Chinese DPP-4 inhibitor, one of Cofrogliptin’s most remarkable features is that it only needs to be taken once every two weeks. This ultra-long dosing interval makes it one of the oral antidiabetic drugs with the lowest dosing frequency currently available worldwide. From “taking medicine every day” to “one pill every two weeks,” the long-acting trend is redefining diabetes treatment.

Why Is Diabetes Treatment Increasingly Focused on “Long-Acting Therapy”?

Diabetes is a chronic disease that often requires lifelong management. As the disease progresses, many patients not only need long-term glucose-lowering medications but also commonly face hypertension, dyslipidemia, obesity, and cardiovascular disease.

During long-term treatment, patients frequently encounter several practical challenges:

●  Multiple daily doses

●  Increased risk of missed or incorrect dosing

●  Declining long-term adherence

●  Unstable blood glucose fluctuations

Studies have shown that patient adherence is closely linked to long-term glycemic control. The more complicated the medication regimen, the harder it usually becomes for patients to maintain consistent treatment over time.

As a result, global diabetes drug development has increasingly emphasized:

●  Long-acting formulations

●  Stable glucose control

●  Simplified dosing schedules

●  Long-term chronic disease management

From once-weekly GLP-1 therapies to now an ultra-long-acting oral drug taken once every two weeks, diabetes treatment has officially entered the “long-acting era.”

What Exactly Is Cofrogliptin?

Cofrogliptin is a DPP-4 inhibitor. Its core mechanism is to inhibit DPP-4 enzyme activity, thereby reducing the degradation of incretin hormones such as GLP-1 and GIP.

Simply put, when GLP-1 levels increase, the body can further:

●  Enhance insulin secretion

●  Suppress glucagon release

●  Improve postprandial glucose control

●  Reduce blood glucose fluctuations

This mechanism shares certain similarities with the increasingly popular GLP-1 therapies, although the pathways are not identical. Compared with some injectable antidiabetic drugs, Cofrogliptin is administered orally, which further improves long-term convenience for patients.

How Is “One Pill Every Two Weeks” Possible?

The most important feature of Cofrogliptin is its ultra-long half-life. Data show that its half-life is approximately 131.5 hours, meaning the drug can maintain stable concentrations in the body for an extended period.

More importantly, even 14 days after administration, DPP-4 enzyme activity can still remain suppressed by over 80%. This is the key reason why the drug can achieve a once-every-two-weeks dosing schedule.

For chronic disease management, reducing dosing frequency not only improves convenience but may also significantly enhance long-term adherence.

Beyond Glucose Control: What Other Potential Advantages Does Cofrogliptin Offer?

As diabetes research continues to advance, the medical community increasingly recognizes that diabetes is not merely “high blood sugar,” but rather a systemic metabolic disease.

Long-term hyperglycemia may affect:

●  The cardiovascular system

●  Kidney function

●  The retina

●  The nervous system

Therefore, modern diabetes drug development now focuses more on “comprehensive metabolic benefits.”

Current data suggest that, beyond stable glucose control, Cofrogliptin may also offer several additional potential advantages. For example, it appears to carry a relatively low risk of hypoglycemia and can be taken regardless of meals. It may also improve certain cardiovascular and renal indicators, including lowering urinary protein levels and improving cardiac function in some patients.

This means that future diabetes treatment goals are no longer limited to “lowering glucose,” but are gradually evolving toward “comprehensive metabolic management.”

Does Long-Acting Mean Safer?

For any long-term chronic medication, safety remains one of the most critical concerns.

Current data indicate that Cofrogliptin is generally well tolerated, although certain potential adverse reactions still require attention, including:

●  Rash and itching

●  Joint pain

●  Liver function abnormalities

●  Elevated amylase or lipase levels

Therefore, during long-term treatment, patients should still undergo regular monitoring of blood glucose, liver function, and related metabolic indicators. Patients with underlying diseases should use the medication under professional medical supervision.

China’s Original Diabetes Drugs Are Entering the Global Long-Acting Era

For many years, the global market for long-acting diabetes drugs was dominated by multinational pharmaceutical companies. Today, however, as China’s innovative drug development capabilities continue to advance, an increasing number of original Chinese chronic disease therapies are attracting international attention.

The significance of Cofrogliptin lies not only in its “one pill every two weeks” dosing innovation, but also in the fact that Chinese pharmaceutical companies are beginning to compete in the global long-acting chronic disease treatment arena.

Looking ahead, as long-acting oral technologies, sustained-release delivery platforms, and intelligent chronic disease management continue to evolve, diabetes treatment models may undergo even greater transformation. From “taking medicine every day” to “once every two weeks,” the era of ultra-long-acting glucose control may only just be beginning.